Completion of Patient Recruitment for International TIGER Study
19 Dec 2022
Brussels, 19 December 2022 – EORTC and Alliance for Clinical Trials in Oncology are pleased to announce that the target accrual in A031102/EORTC1407 TIGER study has been reached.
A031102/EORTC 1407 (TIGER) is an international phase III trial that seeks to establish the standard of care for second-line (also called initial salvage) chemotherapy in patients with advanced germ cell tumors (GCT). TIGER compares initial salvage conventional-dose chemotherapy (CDCT) with the TIP regimen vs. high-dose chemotherapy and autologous stem cell transplant (HDCT/ASCT) with the TI-CE regimen with a primary endpoint of overall survival. The completion of patient recruitment is a major milestone for this groundbreaking trial.
EORTC would like to thank the collaborating groups who have supported this trial, including our funding partner Movember. Without them, this trial would not have been possible in Europe.
“The TIGER trial is significant because collaboration between the Alliance/NCI and EORTC demonstrates that it is possible to conduct investigator-initiated randomized clinical trials in rare malignancies through the cooperative group mechanism in the absence of pharmaceutical company support. To our knowledge, TIGER is the first transatlantic cooperative group-led randomized trial conducted in GCT. This landmark study was open at 63 enters within 13 countries across 3 continents (North America, Europe, and Australia/New Zealand), and has helped pave the way for additional CTEP/NCI-led trials in other rare malignancies via collaboration with EORTC or other international partners.”
– Dr Darren R. Feldman, Study Chair, Memorial Sloan Kettering Cancer Center, US
“The EORTC demonstrated its ability to deliver complex trials in rare cancer. This template can be used in future trials facilitating clinical cancer research.”
– Dr Thomas Powles, EORTC Study Chair, Barts Cancer Institute, UK
Related News
EORTC-1333-GUCG/PEACE III trial endpoint reached
12 Jul 2024
Meet the new EORTC Board
9 Jul 2024
EORTC-1333-GUCG/PEACE III Trial Statement
28 Jun 2024
We are pleased to announce the release of the EORTC 2023 Annual Report
17 Jun 2024
Dr Denis Lacombe, EORTC CEO, appointed stakeholder co-chair of ACT EU advisory group
24 May 2024
Clinical Trials Day 2024: a Q&A on pragmatic clinical trials
20 May 2024
EORTC/EMA workshop suggests an international way forward for treatment optimisation studies
8 May 2024
EORTC’s Participation at the ESTRO Congress 2024
29 Apr 2024
EORTC: Advancing research and treatment for rare cancers
29 Feb 2024
EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration
22 Feb 2024